Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10 11

18 septembre 2018

08:10
Contego Medical announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the first filter-based Integrated Embolic Protection (IEP) device, the Paladin® Carotid PTA Balloon System. Contego Medical is...

08:05
FDA & USDA announced they have approved Phageguard-E as a "GRAS" (Generally Recognized as Safe) food processing aid against E.coli O157. The new product consists of natural phages against E.coli and is produced by Micreos of The Netherlands. The...

08:00
Relmada Therapeutics, Inc. , a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announces that since dosing the first subject on June 27, 2017, 25% of the planned subjects received...

08:00
Evofem Biosciences, Inc., ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, announced today that...

07:05
Viking Therapeutics, Inc. (Viking) , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive top-line results from a 12-week Phase 2 study of VK2809, its...

07:00
CBR® (Cord Blood Registry®), the world's largest newborn stem cell company, has announced the publication of the results of the first clinical trial evaluating the use of autologous umbilical cord blood in children with acquired sensorineural hearing...

05:30
Achieve Life Sciences, Inc. , a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced the publication of new cytisine data from an independent observational...

02:43
Sosei Group Corporation ("Sosei" or the "Company"; TSE Mothers Index: 4565), the world leader in GPCR medicine design and development, announces that the Company and Allergan, its license partner for HTL0018318, have decided to voluntarily suspend...


17 septembre 2018

11:40
A new computer program can analyze images of patients' lung tumors, specify cancer types, and even identify altered genes driving abnormal cell growth, a new study shows.   Led by researchers at NYU School of Medicine and...

11:40
CAMBRIDGE, England, Sept. 17, 2018 /PRNewswire-PRWeb/ -- Fats are an essential part of the human diet. However, excessive consumption leads to overweight, obesity, liver and cardiovascular health problems. The definition of "excess" is highly...

11:00
Scientists at the Allen Institute have used machine learning to train computers to see parts of the cell the human eye cannot easily distinguish. Using 3D images of fluorescently labeled cells, the research team taught computers to find structures...

10:15
Lin BioScience, a drug development company targeting untreatable conditions in oncology, ophthalmology and metabolic diseases, announced today that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to...

09:35
Pulmatrix, Inc. , a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases will present preclinical data on the anti-inflammatory activity of PUR1800 (RV1162) at the ERS International...

09:00
Agenus Inc. , an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced today receipt of a cash milestone from Incyte for the initiation of a Phase 1 clinical trial of...

09:00
Roivant Sciences today announced the launch of Respivant Sciences, a biopharmaceutical company focused on improving the lives of patients suffering from serious respiratory diseases. Respivant will be led by Chief Executive Officer Bill Gerhart,...

08:45
New research in the September 2018 issue of JNCCN?Journal of the National Comprehensive Cancer Network explores a new approach for benchmarking cancer centers, based on how successfully their organizational structures allow them to implement...

08:30
Arena Pharmaceuticals, Inc. today announced that results from preclinical studies of its investigative drug candidate olorinab, a peripherally restricted, highly selective, full agonist of the cannabinoid receptor 2 (CB2) in development for the...

08:30
Theravance Biopharma, Inc. ("Theravance Biopharma") and Mylan N.V. ("Mylan") today announced that positive new data from the companies' Phase 3 clinical program for YUPELRItm (revefenacin) inhalation solution were featured in an oral presentation...

08:01
Sebacia, Inc., a privately held, commercial stage dermatology and aesthetics company, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for its lead product, Sebacia Microparticles. This significant achievement is...

08:00
Results from INPULSIS-ON, published today in Lancet Respiratory Medicine, provide insights into the long-term safety, efficacy and tolerability of Ofev® (nintedanib) in patients with idiopathic pulmonary fibrosis (IPF). These data suggest that the...

08:00
Dr. Michela Gallagher has been named the recipient of the 2018 Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Discovery. The prize, awarded by the Alzheimer's Drug Discovery Foundation (ADDF), recognizes leading researchers developing...

08:00
CartiHeal, developer of the Agili-C implant for the treatment of joint surface lesions, and the Principle Investigator Professor László Hangody, of the Uzsoki Street Hospital, announced today the successful enrollment of the first Hungarian patient...

07:00
Realm Therapeutics plc , a biopharmaceutical company with a proprietary technology platform of stabilized high concentration hypochlorous acid (HOCl), today provides a corporate update following the August 14, 2018 announcement of top-line results of...

07:00
Gala Therapeutics (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced positive results from its First-in-Human trial of RheOxtm in patients with chronic bronchitis.  The data showed a favorable safety...

06:00
Samumed LLC has entered an exclusive license agreement with United Therapeutics Corporation for North American rights to Samumed's SM04646, being developed for the treatment of idiopathic pulmonary fibrosis (IPF). Deal terms include $10 million...

03:00
CartiHeal, développeur de l'implant Agili-C destiné au traitement des lésions de surfaces articulaires, et le professeur László Hangody, chercheur principal travaillant à l'hôpital Uzsoki Street, ont annoncé aujourd'hui l'inscription réussie du...

03:00
CartiHeal, developer of the Agili-C implant for the treatment of joint surface lesions, and the Principle Investigator Professor László Hangody, of the Uzsoki Street Hospital, announced today the successful enrollment of the first Hungarian patient...


16 septembre 2018

12:16
Une analyse additionnelle des données d'une étude mondiale révèle que la qualité de vie est affectée par plusieurs facteurs s'étendant au-delà de la seule gravité de la rosacée  Une analyse additionnelle d'une étude mondiale menée et présentée plus...


15 septembre 2018

01:59
Results on skin clearing, itch and certain quality of life measurements were presented today as a late-breaking oral presentation at the 27th EADV Congress Regeneron Pharmaceuticals, Inc. and Sanofi today presented detailed results from a pivotal...


14 septembre 2018

16:15
Allergan plc today announced clinical study results of higher doses of BOTOX® Cosmetic compared to BOTOX® Cosmetic 20 unit dose at week 24 in patients with moderate to severe glabellar lines. Allergan conducted this...

13:57
Researchers at the University of Maryland School of Medicine (UMSOM) have made a surprising discovery: during fetal development, a particular immune cell seems to play a key role in determining the male or female characteristics of the brain. "This a...

10:57
Cannabics Pharmaceuticals Inc. , a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced it has received encouraging results in its preclinical study showing one of its proprietary cannabinoid compounds...

08:48
Olivia Orano has just delivered baby Myles, a beautiful 7 lbs. baby boy!  Like any first time mother, during the pregnancy, Olivia spent a lot of time developing a "birth plan," or a list of her preferences at time of delivery.  That list originally...

08:00
Sophiris Bio Inc.  (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced...

05:30
Cellesce, the organoid bioprocessing and scale-up company, announces a collaboration with the National Physical Laboratory (NPL), the UK's National Measurement Institute, to image and analyse its range of colorectal cancer organoids. The...


13 septembre 2018

16:31
The National Institutes of Health (NIH) today announced the launch of a new initiative to help speed the development of a cure for sickle cell disease, a group of inherited blood disorders affecting at least 100,000 people in the United States and 20...

16:30
Alimera Sciences, Inc. (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that two presentations will be delivered, and one poster presented, on ILUVIEN® during the 2018 Annual...

16:15
Applied Clinical Informatics recently published "Using Clinical Data Standards to Measure Quality: A New Approach," a peer-reviewed article based on a study utilizing data from the Kansas Health Information Network (KHIN), one of the largest health...

14:30
Professor Cynthia Shannon Weickert at Neuroscience Research Australia (NeuRA) has identified immune cells in greater amounts in the brains of some people with schizophrenia. The study published today in Molecular Psychiatry has the potential to...

13:02
Natera, Inc. , a global leader in cell-free DNA testing, today announced an agreement with Bristol-Myers Squibb to use Natera's Signateratm custom circulating tumor DNA (ctDNA) assay in a Phase 2 study in the adjuvant non-small cell lung cancer...

09:20
AbbVie , a research-based global biopharmaceutical company, today announced new results from the ongoing Phase 2b study including longer-term (32-week) efficacy and safety data and patient-reported outcomes data evaluating upadacitinib, an...

09:00
CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced it has received a milestone payment of $250,000 (USD) from Orphazyme A/S (CPH: ORPHA). The payment is a result of Orphazyme dosing the...

08:51
amg International GmbH (amg), a wholly owned subsidiary of Dublin, Ireland based Q3 Medical Devices Limited (Q3), announced that several clinical cases were performed in Europe with ARCHIMEDES, its new fully biodegradable biliary/pancreatic stent....

08:30
Ampio Pharmaceuticals, Inc. today announced a basic science manuscript entitled "Clinically relevant re-differentiation of fibroblast-like chondrocytes into functional chondrocytes by the low molecular weight fraction of human serum albumin,"...

08:00
Hoffmann-La Roche Limitée (Roche Canada) a annoncé aujourd'hui que Santé Canada a approuvé une préparation sous-cutanée de HERCEPTIN (HERCEPTIN SC) pour le traitement du cancer du sein métastatique au stade précoce surexprimant le récepteur 2 du...

08:00
Hoffmann-La Roche Limited (Roche Canada) announced today that Health Canada has approved a subcutaneous formulation of HERCEPTIN for the treatment of early and metastatic stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer,...

08:00
Boston Biomedical, Inc., a leading developer of novel cancer therapeutics with the goal of significantly improving patient outcomes, today announced that it has initiated clinical trial activities for DSP-0509, an investigational Toll-like receptor...

08:00
Array BioPharma Inc. today announced the publication of detailed overall survival (OS) results from the COLUMBUS trial in The Lancet Oncology. The pivotal Phase 3 trial evaluated the efficacy and safety of the combination of BRAFTOVI®+ MEKTOVI®...

08:00
Bird Rock Bio, Inc., a clinical stage biopharmaceutical company, announced today that it has successfully completed its final patient visit in the Phase Ib multiple ascending dose trial in patients with non-alcoholic fatty liver disease (NAFLD) and...

07:00
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) of EYLEA® (aflibercept) Injection for the treatment of diabetic...

1 2 3 4 5 6 7 8 9 10 11